Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Previous PostImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers